Monitoring Agency Report for the quarter ended 31st March, 2026
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings Limited submitted its quarterly monitoring report for Akums Drugs' IPO proceeds utilization as of March 31, 2026. The company raised Rs 6,800 million via IPO in July-August 2024, with net proceeds of Rs 6,421.80 million after issue expenses of Rs 377.23 million. Of the net proceeds, Rs 6,373.70 million (99.3%) has been utilized, leaving Rs 48.10 million unutilized. All major deployment objects—debt repayment (Rs 3,870 million), working capital (Rs 550 million), acquisitions (Rs 278.70 million of Rs 301.80 million revised), and general corporate purposes (Rs 1,675 million of Rs 1,700 million revised)—are on track. There is a minor delay in inorganic growth spending (planned FY25, utilized FY26) but the prospectus allows carry-forward to next fiscal. No material deviations or unfavorable events were reported.
The IPO proceeds are being deployed largely as planned with only minor delays in acquisition spending. The Rs 48.10 million remaining will support ongoing acquisition activities and general corporate needs. Shareholders can note healthy utilization pace and no red flags from the independent monitoring agency.